8-K

XOMA CORPORATION

Date: April 25, 2024

/s/ THOMAS BURNS

Thomas Burns

Senior Vice President, Finance and Chief Financial Officer

0001193125-24-111613.txt : 20240425 0001193125-24-111613.hdr.sgml : 20240425 20240425080736 ACCESSION NUMBER: 0001193125-24-111613 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240425 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240425 DATE AS OF CHANGE: 20240425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XOMA Corp CENTRAL INDEX KEY: 0000791908 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 522154066 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39801 FILM NUMBER: 24873098 BUSINESS ADDRESS: STREET 1: 2200 POWELL STREET STREET 2: SUITE 310 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-204-7239 MAIL ADDRESS: STREET 1: 2200 POWELL STREET STREET 2: SUITE 310 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: XOMA LTD /DE/ DATE OF NAME CHANGE: 19990107 FORMER COMPANY: FORMER CONFORMED NAME: XOMA CORP /DE/ DATE OF NAME CHANGE: 19920703 8-K 1 d815676d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): April 25, 2024

XOMA CORPORATION

(Exact Name of Registrant as Specified in Charter)


DELAWARE	001-39801	52-2154066
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

2200 Powell Street, Suite 310, Emeryville, California 94608

(Address of Principal Executive Offices) (Zip Code)

(510) 204-7200

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class:	Trading symbol(s):	Name of each exchange on which registered:
Common Stock, $0.0075 par value	XOMA	The Nasdaq Global Market
8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share	XOMAP	The Nasdaq Global Market
Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share)	XOMAO	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events.

On April 25, 2024, XOMA Corporation issued a press release announcing that it earned a $9 million milestone related to the U.S. Food and Drug Administration’s (FDA) approval of Day One Biopharmaceuticals’ New Drug Application (NDA) for OJEMDA^™ (tovorafenib) for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

A copy of the press release described above is attached hereto as Exhibit 99.1.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.		Description

99.1		Press Release, dated April 25, 2024

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-99.1 2 d815676dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDA^TM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

XOMA is entitled to a mid-single digit royalty on global OJEMDA^™ sales

First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation

EMERYVILLE, Calif. – April 25, 2024 (GLOBE NEWSWIRE) – XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $9 million milestone related to the U.S. Food and Drug Administration’s (FDA) approval of Day One Biopharmaceuticals’ New Drug Application (NDA) for OJEMDA^™ (tovorafenib) for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

“This is an important milestone for XOMA and our royalty portfolio, but more importantly, it is a watershed event for children living with low-grade gliomas with BRAF alterations that have relapsed or progressed,” stated Owen Hughes, Chief Executive Officer of XOMA.

In March 2021, XOMA paid $13.5 million upfront to acquire the $54 million in potential milestones and mid-single digit royalties associated with tovorafenib, plus a share of potential event-based economics, in addition to the economics associated with vosaroxin, from Viracta Therapeutics.

About XOMA Corporation

XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.

Forward-Looking Statements/Explanatory Notes

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial payments to XOMA and other developments related to OJEMDA^™ (tovorafenib) and the potential of XOMA’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time. In some cases, you can identify such forward-looking statements by terminology such as “expect,” “may,” “will”, or “could,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them; and the impact to the global economy as a result of the COVID-19 pandemic. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA’s most recent filing on Form 10-K and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA’s prospects. Any forward-looking statement in this press release represents XOMA’s beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.

EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.

As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio, except OJEMDA^™ (tovorafenib), VABYSMO^® (faricimab-svoa), IXINITY^® [coagulation factor IX (recombinant)], DSUVIA^® (sufentanil sublingual tablet), are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available.


XOMA Investor Contact		XOMA Media Contact

Juliane Snowden		Kathy Vincent
XOMA Corporation		KV Consulting & Management
+1 646-438-9754		+1 310-403-8951
juliane.snowden@xoma.com		kathy@kathyvincent.com

###

EX-101.SCH 3 xoma-20240425.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 xoma-20240425_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 xoma-20240425_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Series A Preferred Stock [Member] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Series B Preferred Stock [Member] EX-101.PRE 6 xoma-20240425_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g815676g0425112613166.jpg GRAPHIC begin 644 g815676g0425112613166.jpg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htm IDEA: XBRL DOCUMENT

Document and Entity Information	Apr. 25, 2024
Document And Entity Information [Line Items]
Entity Registrant Name	XOMA Corp
Entity Incorporation State Country Code	DE
Amendment Flag	false
Entity Central Index Key	0000791908
Document Type	8-K
Document Period End Date	Apr. 25, 2024
Entity File Number	001-39801
Entity Tax Identification Number	52-2154066
Entity Address, Address Line One	2200 Powell Street
Entity Address, Address Line Two	Suite 310
Entity Address, City or Town	Emeryville
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94608
City Area Code	(510)
Local Phone Number	204-7200
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock [Member]
Document And Entity Information [Line Items]
Security 12b Title	Common Stock, $0.0075 par value
Trading Symbol	XOMA
Security Exchange Name	NASDAQ
Series A Preferred Stock [Member]
Document And Entity Information [Line Items]
Security 12b Title	8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share
Trading Symbol	XOMAP
Security Exchange Name	NASDAQ
Series B Preferred Stock [Member]
Document And Entity Information [Line Items]
Security 12b Title	Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share)
Trading Symbol	XOMAO
Security Exchange Name	NASDAQ

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 4 23 1 false 3 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityIncorporationStateCountryCode, dei:EntityRegistrantName - d815676d8k.htm 7 d815676d8k.htm xoma-20240425.xsd xoma-20240425_def.xml xoma-20240425_lab.xml xoma-20240425_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d815676d8k.htm": { "nsprefix": "xoma", "nsuri": "http://www.xoma.com/20240425", "dts": { "inline": { "local": [ "d815676d8k.htm" ] }, "schema": { "local": [ "xoma-20240425.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "definitionLink": { "local": [ "xoma-20240425_def.xml" ] }, "labelLink": { "local": [ "xoma-20240425_lab.xml" ] }, "presentationLink": { "local": [ "xoma-20240425_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 3, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 4, "entityCount": 1, "segmentCount": 3, "elementCount": 31, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-04-25_to_2024-04-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d815676d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-04-25_to_2024-04-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d815676d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "xoma_DocumentAndEntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.xoma.com/20240425", "localname": "DocumentAndEntityInformationLineItems", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "auth_ref": [] }, "xoma_DocumentAndEntityInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.xoma.com/20240425", "localname": "DocumentAndEntityInformationTable", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock [Member]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.xoma.com//20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001193125-24-111613-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-111613-xbrl.zip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end XML 20 d815676d8k_htm.xml IDEA: XBRL DOCUMENT 0000791908 2024-04-25 2024-04-25 0000791908 us-gaap:CommonStockMember 2024-04-25 2024-04-25 0000791908 us-gaap:SeriesAPreferredStockMember 2024-04-25 2024-04-25 0000791908 us-gaap:SeriesBPreferredStockMember 2024-04-25 2024-04-25 XOMA Corp DE false 0000791908 8-K 2024-04-25 001-39801 52-2154066 2200 Powell Street Suite 310 Emeryville CA 94608 (510) 204-7200 false false false false Common Stock, $0.0075 par value XOMA NASDAQ 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share XOMAP NASDAQ Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share) XOMAO NASDAQ false